Search company, investor...



Incubator/Accelerator | Alive

About GROM

GROM allows doctors to offer corrective footwear by using 3D printing to replicate a prescription and integrate it directly into a shoe's footbed. Its app is equipped with 3D scanning that allows the user to quickly measure patients' feet without casting and complete and share prescription forms.

Headquarters Location

Hong Kong

Missing: GROM's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: GROM's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing GROM

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

GROM is included in 1 Expert Collection, including Pharma Supply Chain.


Pharma Supply Chain

1,258 items

Latest GROM News

UBS upgrades Procter & Gamble, says household goods giant can rally nearly 20%

Mar 3, 2023

March 3, 2023 - Advertisement - Now is the time to buy Procter & Gamble, which sees the company’s recent poor performance as “unjustified,” according to UBS. Analyst Peter Thunder upgraded Procter’s stock to $163 from $157 before the buy. The new outlook suggests 18% upside from Tuesday’s closing price. “P&G stocks performed the worst of any of our [home and personal care] year-to-date coverage, partly due to the weakening of the group, but also concerns about P&G’s ability to generate significant earnings-per-share growth / positive developments going forward,” Grom wrote in a note on Tuesday. “We are considering concerns about the latter. as irrelevant and believe that FY24 earnings are expected to change on the horizon,” he said. The analyst also noted that Procter shares are trading slightly below their five-year average valuation, making “risk/reward at current levels attractive.” Grom added that a return to stock gains, premiumization and a reopening in China lead to organic revenue growth estimates of nearly 5% in 2024. while we believe this has been a key reason for P&G’s lagging YTD, we see upside potential in FY24 consensus forecasts,” Grom said. P&G stock is down more than 9% in 2023, while the S&P 500 is up 3.4% in that time. added 1.4% in premarket on Wednesday. — Michael Bloom of CNBC Credit: /

GROM Frequently Asked Questions (FAQ)

  • What is GROM's latest funding round?

    GROM's latest funding round is Incubator/Accelerator.

  • Who are the investors of GROM?

    Investors of GROM include MaGIC Global Accelerator Programme.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.